Keytruda’s Initial FDA Approval Year Keytruda (pembrolizumab) received its first FDA approval on September 4, 2014,… https://www.Drugchatter.com/chat/49405/keytruda’s-fda-approval-can-you-name-the-year/

Keytruda’s Initial FDA Approval Year Keytruda (pembrolizumab) received its first FDA approval on September 4, 2014,… https://www.Drugchatter.com/chat/49405/keytruda’s-fda-approval-can-you-name-the-year/

Generic drug “freedom to operate” isn’t about finding one loophole—it’s about designing a whole strategy.
In the patent world, the phrase “picket fence” gets used to describe a familiar trap: a cluster of overlapping patents that can make it look lik…

Drug patents in Africa: how long they really last—and why it matters more than ever
If you’ve ever wondered why some medicines stay expensive for years while others suddenly become affordable, the answer often isn’t “market forces.” It’s patent life—an…

🚦 Green light for launch? Not so fast—your FTO analysis can make or break the first day of revenue.
In pharma, the moment you announce a “launch-ready” product, the clock starts ticking—not just on manufacturing timelines, but on patent risk. A sing…

Biotech investors don’t lose money because they can’t read a press release.
They lose money because they read the wrong numbers.
In a sector where one trial update can swing a stock 30% in a day, “headline metrics” are often just noise—useful for story…

Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System (Explained)
In pharma, “protection” isn’t one thing—it’s two.
And if you’re an investor, operator, or policy watcher, understanding the difference between patent exclusi…

First-to-File, First-to-Profit: The Hidden Math Behind Paragraph IV and 180-Day Exclusivity
If you’ve ever wondered why some generic launches feel like they happen “overnight” while others drag on for years, the answer is often sitting in a single phra…

Generic and biosimilar launches don’t fail because the science is wrong—they fail because the timing is.
In managed care, pharmacy teams live in the uncomfortable gap between regulatory reality and contractual execution. A product loses exclusivity, …

Most pharma teams don’t lose because they’re out of talent. They lose because they’re out of time.
By the time a competitor’s “official” pipeline hits the public domain—conference slides, press releases, even the first whispers in a journal—your window…